Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product
Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT trial
Telix Pharmaceuticals Limited is pleased to announce that the US Food and Drug Administration (FDA) has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT trial design for the development of Telix’s prostate cancer therapy product TLX591 (177Lu-DOTA-rosopatamab) in patients with metastatic castration-resistant prostate cancer (mCRPC) that express Prostate-Specific Membrane Antigen (PSMA).
To read full media release please click here.